DIA Bioventure Day

Holger G Adelmann, Senior VP and Managing Director, DIA EMEA, Switzerland
Kerry Sharp, Head Scottish Investment Bank, UK

Helga Ruebsamen-Schaeff, Chair Of The Board, Aicuris, Germany

Session 1 will set the scene for most of the day by exploring key challenges that the biotech-ecosystem, pharmaceutical innovators, and ultimately the patients that are expecting innovative cures are facing nowadays. Key stakeholders from the biotech industry, regulatory/payer area, and research in the economic & scientific policy field will share their recent insights and perspectives.

• Europe’s flawed and underfunded Biotech-ecosystem (EBE position paper)
  Barbara Freischem, Executive Director, European Biopharmaceutical Enterprises (EBE), Belgium
• Is Parallel Micro-Innovation Overburdening the Health Care System?
  Luca Pani, CHMP Member, former AIFA, Italy
• Links between Pharmaceutical R&D Models and Access to Affordable Medicines
  Wija Oortwijn, Partner / Manager Sector Health, Ecorys (lead researcher of a recent EU Parliament publication), The Netherlands

Session 2 will review innovative ways to fund private and public enterprises and to ensure patients with rare diseases are not being forgotten. Experienced Investors will share different approaches to fund innovative cure.

• Funding Private & Public Enterprises
  Joep Muijrers, Partner, Life Science Partners, USA
• Crowdfunding
  Emily Crossley, co-founder and joint CEO, Duchenne, UK
• Funding Innovation
  EU Investment Bank, Speaker invited
• Megafunds: Concept Introduction & Discussion
  Dimitrios Athanasiou, Duchenne Patient Advocate; Patient expert, European Medicines Agency, European Union

Agnès Saint Raymond, Head of International Affairs, European Medicines Agency, European Union

This presentation & discussion will be a rich source of inspiration for all health care stakeholders.

Moderator: Helga Ruebsamen-Schaeff, Chair of the Board, AiCuris, Germany

Panellists:

• Regulator and Payer View: Luca Pani, CHMP Member, former AIFA, Italy
• Academia View: John Dillon, Professor of Hepatology, Dundee University, UK
• Venture Capitalist Perspective: Joep Muijrers, Partner, Life Science Partners, USA
• Industry View: Representative invited
• Patient View: Tamas Bereczky, Communications Officer, European AIDS Treatment Group, Hungary
• HTA Body View: Ailsa Brown, Lead Health Economist, Scottish Medicines Consortium, UK
• Payer View: Menno Aarnout, Executive Director, AIM, Belgium

Moderator: Duane Schulthess, Managing Director, Vital Transformation, Belgium

Panellists:

• Regulator View: Tomas Salmonson, CHMP Chair, MPA, Sweden
• Academia View: Stefan Symeonides, Edinburg Cancer Research Centre, UK
• Product Partnership Perspective: Wolfgang Stoiber, Managing Director, JSB-Partners, USA
• Biotech View: Mariola Soehngen, CEO, Mologen, Germany
• Companion Diagnostics View: Kamala Maddali, Cancer Genetics Inc., USA
• Big Pharma View: Alexander Roediger, Policy Lead – Oncology for EMEA & Canada, MSD, Switzerland
• Patient View: Bettina Ryll, Founder, Melanoma Patient Network Europe, Sweden
• HTA Body View: Alan Macdonald, Vice Chair, Scottish Medicines Consortium, UK
• Payer View: Menno Aarnout, Executive Director, AIM, Belgium

Poster Moderators:

• Joep Muijrers, Partner, Life Science Partners, USA
• David Haerry, Member of Board of Directors, European AIDS Treatment Group, Belgium

Topics for posters:

• BioVenture success stories
• BioVenture hurdles and how to overcome them
• New BioVenture Business Plans